| Company Name: |
NanJing Xienuo bio Co.,Ltd.
|
| Tel: |
025-84112752 13805181430 |
| Email: |
154301870@qq.com |
| Products Intro: |
Product Name:2-Propenamide, N-[(3R,4S)-4-[[6-(2,6-dichloro-3,5-dimethoxyphenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]tetrahydro-3-furanyl]-
CAS:1628793-01-0
Purity:97% Package:500mg 1g 5g
|
| Company Name: |
Shanghai Yifei Biotechnology Co. , Ltd.
|
| Tel: |
021-65675885 18964387627 |
| Email: |
customer_service@efebio.com |
| Products Intro: |
Product Name:FGFR4-IN-5
CAS:1628793-01-0
Purity:95.00% Package:2mg;25mg;50mg
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:FGFR4-IN-5
CAS:1628793-01-0
Package:2mg/RMB 2490;25mg/RMB 11700;50mg/RMB 15300
|
2-Propenamide, N-[(3R,4S)-4-[[6-(2,6-dichloro-3,5-dimethoxyphenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]tetrahydro-3-furanyl]- manufacturers
- FGFR4-IN-5
-
- $2180.00 / 50mg
-
2026-01-05
- CAS:1628793-01-0
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | 2-Propenamide, N-[(3R,4S)-4-[[6-(2,6-dichloro-3,5-dimethoxyphenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]tetrahydro-3-furanyl]- Basic information |
| Product Name: | 2-Propenamide, N-[(3R,4S)-4-[[6-(2,6-dichloro-3,5-dimethoxyphenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]tetrahydro-3-furanyl]- | | Synonyms: | 2-Propenamide, N-[(3R,4S)-4-[[6-(2,6-dichloro-3,5-dimethoxyphenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]tetrahydro-3-furanyl]-;FGFR4-IN-5;FGFR4 IN 5,FGFR-4-IN-5,FGFR4IN5;FGFR4-IN-2 | | CAS: | 1628793-01-0 | | MF: | C23H23Cl2N5O5 | | MW: | 520.37 | | EINECS: | | | Product Categories: | | | Mol File: | 1628793-01-0.mol | ![2-Propenamide, N-[(3R,4S)-4-[[6-(2,6-dichloro-3,5-dimethoxyphenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]tetrahydro-3-furanyl]- Structure](CAS/20210305/GIF/1628793-01-0.gif) |
| | 2-Propenamide, N-[(3R,4S)-4-[[6-(2,6-dichloro-3,5-dimethoxyphenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]tetrahydro-3-furanyl]- Chemical Properties |
| density | 1.47±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 100 mg/mL (192.17 mM; Need ultrasonic) | | form | Solid | | pka | 13.65±0.40(Predicted) | | color | White to off-white |
| | 2-Propenamide, N-[(3R,4S)-4-[[6-(2,6-dichloro-3,5-dimethoxyphenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]tetrahydro-3-furanyl]- Usage And Synthesis |
| Uses | FGFR4-IN-5 is a potent and selective covalent FGFR4 inhibitor with an IC50 of 6.5 nM. FGFR4-IN-5 exhibits strong anti-tumor activity in vivo and can be used for hepatocellular carcinoma research[1]. | | Biological Activity | FGFR4-IN-5 is a potent and selective covalent FGFR4 inhibitor with an IC50 of 6.5 nM. FGFR4-IN-5 exhibits strong anti-tumor activity in vivo and can be used for hepatocellular carcinoma research[1].
FGFR4-IN-5 (oral gavage; 10 mg/kg; single dose) reveals a high Cmax, low clearance, the Cmax values are 423 ng/ml, 588 ng/ml, and 2820 ng/ml in mice, rat and cynamolgus monkey, respectively. And the oral bioavailability are 20, 12, and 27% in mouse, rat, and cyno, respectively[1].FGFR4-IN-5 (oral gavage; 100 mg/kg; twice daily; 28 days) exhibits strong antitumor activity in an orthotopic Hep3B HTX model[1].FGFR4-IN-5 (oral gavage; 10, 30, and 100 mg/kg; twice daily; 11 days) results in dose-dependent growth inhibition of resistant tumors. Tumor regression is observed at 30 and 100 mg/kg, with %δT/δC of 67% and 70%, respectively. However, treatment with sorafenib at 100 mg/kg once daily does not provide any benefit in vivo[1]. | | in vivo | FGFR4-IN-5 (oral gavage; 10 mg/kg; single dose) reveals a high Cmax, low clearance, the Cmax values are 423 ng/ml, 588 ng/ml, and 2820 ng/ml in mice, rat and cynamolgus monkey, respectively. And the oral bioavailability are 20, 12, and 27% in mouse, rat, and cyno, respectively[1].FGFR4-IN-5 (oral gavage; 100 mg/kg; twice daily; 28 days) exhibits strong antitumor activity in an orthotopic Hep3B HTX model[1].FGFR4-IN-5 (oral gavage; 10, 30, and 100 mg/kg; twice daily; 11 days) results in dose-dependent growth inhibition of resistant tumors. Tumor regression is observed at 30 and 100 mg/kg, with %ΔT/ΔC of 67% and 70%, respectively. However, treatment with sorafenib at 100 mg/kg once daily does not provide any benefit in vivo[1]. | Animal Model: | Hep3B cell bearing mice model[1] | | Dosage: | 100 mg/kg | | Administration: | Oral gavage; 100 mg/kg; twice daily; 28 days | | Result: | Resulted in tumor regression and sustained growth inhibition. |
| Animal Model: | Sorafenib-resistant tumors established to mice bearing Huh7 tumors[1] | | Dosage: | 10, 30, and 100 mg/kg | | Administration: | Oral gavage; 10, 30, and 100 mg/kg; twice daily; 11 days | | Result: | Resulted in dose-dependent growth inhibition of resistant tumors. |
| | IC 50 | FGFR4: 6.5 nM (IC50); FGFR2: 505 nM (IC50) | | References | [1]. Haibo Liu, et al. Discovery of Selective, Covalent FGFR4 Inhibitors with Antitumor Activity in Models of Hepatocellular Carcinoma. ACS Med Chem Lett. 2020 Mar 6;11(10):1899-1904. |
| | 2-Propenamide, N-[(3R,4S)-4-[[6-(2,6-dichloro-3,5-dimethoxyphenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]tetrahydro-3-furanyl]- Preparation Products And Raw materials |
|